These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36680177)

  • 1. Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?
    Meunier L; Belkacemi M; Pageaux GP; Radenne S; Vallet-Pichard A; Houssel-Debry P; Duvoux C; Botta-Fridlund D; de Ledinghen V; Conti F; Anty R; Di Martino V; Debette-Gratien M; Leroy V; Gerster T; Lebray P; Alric L; Abergel A; Dumortier J; Besch C; Montialoux H; Samuel D; Duclos-Vallée JC; Coilly A
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.
    Pascasio JM; Vinaixa C; Ferrer MT; Colmenero J; Rubin A; Castells L; Manzano ML; Lorente S; Testillano M; Xiol X; Molina E; González-Diéguez L; Otón E; Pascual S; Santos B; Herrero JI; Salcedo M; Montero JL; Sánchez-Antolín G; Narváez I; Nogueras F; Giráldez Á; Prieto M; Forns X; Londoño MC
    J Hepatol; 2017 Dec; 67(6):1168-1176. PubMed ID: 28842296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting.
    Perricone G; Duvoux C; Berenguer M; Cortesi PA; Vinaixa C; Facchetti R; Mazzarelli C; Rockenschaub SR; Martini S; Morelli C; Monico S; Volpes R; Pageaux GP; Fagiuoli S; Belli LS;
    Liver Int; 2018 Dec; 38(12):2170-2177. PubMed ID: 29750389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
    Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
    World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
    Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
    Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate.
    Daniel KE; Said A
    Curr Gastroenterol Rep; 2018 Apr; 20(5):20. PubMed ID: 29623506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation.
    Emamaullee JA; Bral M; Meeberg G; Montano-Loza AJ; Bain VG; Burak KW; Bigam D; Shapiro AMJ; Kneteman N
    Can J Gastroenterol Hepatol; 2019; 2019():2509059. PubMed ID: 30775356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience.
    Nabatchikova EA; Abdurakhmanov DT; Rozina TP; Nikulkina EN; Tanaschuk EL; Moiseev SV
    Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101714. PubMed ID: 33930587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy.
    Vaziri A; Gimson A; Agarwal K; Aldersley M; Bathgate A; MacDonald D; McPherson S; Mutimer D; Gelson W
    J Viral Hepat; 2019 Feb; 26(2):231-235. PubMed ID: 30339294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of hepatitis C-related liver transplantation in direct-acting antiviral era.
    Choudhary NS; Saraf N; Saigal S; Rastogi A; Bhangui P; Thiagrajan S; Soin AS
    Indian J Gastroenterol; 2020 Dec; 39(6):539-543. PubMed ID: 33230754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement.
    Pose E; Torrents A; Reverter E; Perez-Campuzano V; Campos-Varela I; Avitabile E; Gratacós-Ginès J; Castellote J; Castells L; Colmenero J; Tort J; Ginès P; Crespo G
    J Hepatol; 2021 Aug; 75(2):275-283. PubMed ID: 33746085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study.
    Gorgen A; Galvin Z; Huang AC; Vinaixa C; O'Rourke JM; Francoz C; Hansen BE; Durand F; Elsharkawy AM; Shah T; Berenguer M; Rubin A; Calatayud D; Mehta N; Terrault NA; Lilly LB; Selzner N; Sapisochin G
    Transplantation; 2020 Oct; 104(10):2087-2096. PubMed ID: 31978002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study.
    Pereira GH; Peixoto HR; Giusti ML; Souza ML; Victor LB; Fernandes F; Perez RM; Villela-Nogueira CA
    Braz J Infect Dis; 2022; 26(5):102697. PubMed ID: 36037847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.
    Belli LS; Berenguer M; Cortesi PA; Strazzabosco M; Rockenschaub SR; Martini S; Morelli C; Donato F; Volpes R; Pageaux GP; Coilly A; Fagiuoli S; Amaddeo G; Perricone G; Vinaixa C; Berlakovich G; Facchetti R; Polak W; Muiesan P; Duvoux C;
    J Hepatol; 2016 Sep; 65(3):524-31. PubMed ID: 27212241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence.
    Piñero F; Boin I; Chagas A; Quiñonez E; Marciano S; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Mendizabal M; Hurtado Gomez S; Stucchi R; Maccali C; Vergara Sandoval R; Bermudez C; McCormack L; Varón A; Gadano A; Mattera J; Rubinstein F; Carrilho F; Silva M
    Liver Transpl; 2020 May; 26(5):640-650. PubMed ID: 32133773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience.
    Martini S; Donato MF; Mazzarelli C; Rendina M; Visco-Comandini U; Filì D; Gianstefani A; Fagiuoli S; Melazzini M; Montilla S; Pani L; Petraglia S; Russo P; Trotta MP; Carrai P; Caraceni P;
    Liver Int; 2018 Apr; 38(4):733-741. PubMed ID: 28921807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT).
    Sáez-González E; Vinaixa C; San Juan F; Hontangas V; Benlloch S; Aguilera V; Rubín A; García M; Prieto M; López-Andujar R; Berenguer M
    Liver Int; 2018 Jun; 38(6):1022-1027. PubMed ID: 29105320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
    J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.